Table II.
Characteristics of study participants at each visit
| Characteristics | CF (n = 29) |
Controls∗ (n = 18) | ||
|---|---|---|---|---|
| Entry (n = 28) | 2-wk visit (n = 11) | 12-wk visit (n = 26) | ||
| Age, y | 6.9 (2.8-10.9) | 3.2 (2.4-9.3) | 9.3 (3.0-11.7) | 13.3 (11.3-15.9) |
| Male/female | 18 (64)/10 (36) | 7 (64)/4 (36) | 17 (65)/9 (35) | 5 (28)/13 (72) |
| Distance from CF center,† km | 111 (53-217) | 53 (51-63) | 76 (53-212) | |
| Modulator(s) | 19 (68) | 7 (64) | 18 (69) | |
| Elexacaftor/tezacaftor/ivacaftor | 11 (39) | 3 (27) | 12 (46) | |
| Ivacaftor | 3 (11) | 2 (18) | 3 (12) | |
| Lumacaftor/ivacaftor | 1 (4) | 1 (9) | 2 (8) | |
| Tezacaftor/ivacaftor | 1 (4) | 1 (9) | 1 (4) | |
| Pancreatic insufficiency‡ | 25 (89) | 9 (82) | 23 (88) | |
| Proton-pump inhibitor | 20 (71) | 9 (82) | 17 (65) | |
| Long-term oral azithromycin | 8 (29) | 1 (9) | 8 (31) | |
| Weight-for-age z score§ | 0.12 (−0.45 to 0.67) | 0.48 (0.12-1.35) | 0.24 (−0.51 to 0.76) | 0.255 (−0.6 to 0.69) |
| Height-for-age z score§ | 0.01 (−0.65 to 0.47) | 0.42 (−0.12 to 0.53) | −0.01 (−0.30 to 0.37) | −0.48 (−1.00 to 0.32) |
| Weight-for-length/height z score§ | 0.59 (0.09-0.86) | 0.73 (0.30-0.88) | 0.23 (−0.12 to 0.8) | n/a |
| BMI z score§ | 0.20 (−0.09 to 0.97) | 1.05 (0.76-1.61) | 0.38 (−0.47 to 1.33) | 0.04 (−0.73 to 0.82) |
| IV antibiotics in past 3 mo | 0 (0) | 0 (0) | 1 (4) | |
| Oral antibiotics in past week | 4 (14) | 1 (9) | 1 (4) | |
| Diagnosis of CF liver disease | 4 (14) | 2 (18) | 4 (15) | |
| Abdominal pain in past month | ||||
| None | 13 (50) | 6 (55) | 14 (70) | |
| Once a week | 8 (31) | 3 (27) | 2 (10) | |
| 2-3 times per week | 4 (15) | 1 (9) | 4 (20) | |
| 4-5 times per week | 1 (4) | 1 (9) | 0 (0) | |
| Stool provided | 25 (89) | 10 (91) | 22 (85) | 12 (75) |
| Blood provided | 28 (100) | 10 (91) | 22 (85) | 16 (89) |
IV, intravenous; n/a, not applicable.
Values expressed as median (IQR) or n (percent).
†
Calculated as shortest driving distance from street address of primary residence to St Louis Children’s Hospital in Google Maps in May 2023.
‡
Pancreatic insufficiency defined as those who have low concentrations of fecal elastase, 2 severe mutations, or who are prescribed pancreatic enzyme replacements.
§
As published in Kuczmarski et al.23